P53,ki-67,galectin-3,HBME-1,34βE12和CK19在甲状腺乳头状癌中的表达及临床病理意义

摘要

Objective To investigate the expression of P53 , ki-67, galectin-3, HBME-1, 34pE12 and CK-19 in the papillary thyroid carcinomas and clinical pathology significance. Methods By s-p immunohistochemical technique, the expression of P53 , ki-67 , galectin-3 , HBME-1, 34βE12 and CK-19 was detected in 43 cases of papillary thyroid carcinomas, 37 multinodular goiters, 33 follicular adenomas and 17 Hashimoto's thyroiditis. Results The expression rate of P53, ki-67, galectin-3, HBME-1, 34βE12 and CK19 in the papillary thyroid carcinomas was 88. 37% , 79. 07% , 88. 37% , 93. 02% , 86. 05% and 95. 35% respectively. The expression rate of P53 , ki-67 , galectin-3, HBME-1, 34βE12 and CK19 in the multinodular goiters was 18. 92% ,29. 73% ,27. 03% , 16. 22% , 24. 32% 和5. 41% respectively. Expression of P53, ki-67, galectin-3, HBME-1, 34βE12 and CK-19 were obviously different in the papillary thyroid carcinomas and benign lesions (P <0. 01). Conclusion Combined application of immunohistochemical staining of P53 , ki-67 , galectin-3 , HBME-1 , 34βE12 and CK-19 is a potential method to differentiate papillary thyroid carcinoma and benign lesions.%目的 探讨P53,ki-67,galectin-3,HBME-1,34βE12和CK-19在甲状腺乳头状癌中的表达及临床病理意义.方法 采用免疫组化检测43例甲状腺乳头状癌,37例结节性甲状腺肿,33例甲状腺腺瘤和17例桥本甲状腺炎中P53,ki-67,galectin-3,HBME-1,34βE12和CK-19的表达.结果 P53,ki-67,galectin-3,HBME-1,34βE12和CK-19在甲状腺乳头状癌中的阳性表达率分别为88.37％、79.07％、88.37％、93.02％、86.05％及95.35％,显著高于结节性甲状腺肿的18.92％、29.73％、27.03％、16.22％、24.32％和5.41％(P＜0.05);也高于甲状腺腺瘤和桥本甲状腺炎中的阳性表达率(P＜0.01).结论 联合检测P53,ki-67,galectin-3,HBME-1,34pE12和CK-19在诊断和鉴别诊断甲状腺乳头状癌与良性病变中具有重要的价值.